What dose of enoxaparin (Lovenox) should be given when holding apixaban (Eliquis) for a left heart catheterization in a 141‑lb patient?

Bridging Anticoagulation for Left Heart Catheterization

For a 141-lb (64 kg) patient holding Eliquis for left heart catheterization, you should NOT routinely use bridging enoxaparin—simply hold the Eliquis and proceed with the catheterization using standard periprocedural anticoagulation (UFH or bivalirudin) at the time of the procedure.

Key Clinical Reasoning

The evidence provided focuses on acute coronary syndrome (ACS) management and perioperative bridging for patients on chronic anticoagulation. Your scenario—a diagnostic left heart catheterization—differs fundamentally:

Why Bridging is NOT Indicated

• Left heart catheterization is a low-bleeding-risk procedure that typically requires only brief interruption of anticoagulation (24-48 hours for apixaban)
• The 2022 CHEST guidelines 1 for perioperative antithrombotic management do not recommend bridging for DOACs in most clinical scenarios, as DOACs have short half-lives and predictable offset
• Bridging increases bleeding risk without clear benefit for diagnostic procedures

Appropriate Management Strategy

Hold Eliquis:

• Stop apixaban 48 hours before the procedure (2 half-lives for normal renal function)
• If CrCl 30-50 mL/min: hold 72 hours before
• If CrCl 15-30 mL/min: hold 96 hours before

At Time of Catheterization:

• Use UFH 70-100 U/kg IV bolus to achieve ACT 250-300 seconds during the procedure 2, 3
• Alternatively, bivalirudin 0.75 mg/kg bolus followed by 1.75 mg/kg/h infusion during PCI if intervention is anticipated 2, 3

Resume Eliquis:

• Restart 24 hours post-procedure for diagnostic catheterization
• If intervention performed with stenting, restart 24-48 hours post-procedure depending on bleeding risk

If Bridging Were Absolutely Required (High Thrombotic Risk)

Only in exceptional circumstances (e.g., mechanical mitral valve, recent VTE within 3 months, severe thrombophilia) would bridging be considered:

Enoxaparin dosing for 64 kg patient:

• 1 mg/kg subcutaneous every 12 hours = 64 mg (approximately 60 mg) subcutaneously every 12 hours 2, 3, 2
• Last dose should be given 24 hours before the procedure (not the morning of)
• Resume 24-48 hours post-procedure at same dose until therapeutic INR if transitioning to warfarin, or resume Eliquis directly

Critical Pitfalls to Avoid

• Do not bridge routinely—this is the most common error and increases bleeding without benefit for diagnostic procedures
• Do not give enoxaparin the morning of the procedure—this creates excessive anticoagulation during catheterization
• Do not use fondaparinux for catheterization support—it increases catheter thrombosis risk 2, 3
• Verify renal function before dosing decisions, as apixaban clearance is renally dependent

The evidence clearly shows that for elective procedures like diagnostic catheterization, simple interruption of the DOAC with appropriate periprocedural anticoagulation is superior to bridging therapy in terms of both safety and efficacy 1.